Company Analysis
Sign in

Omeros Corporation (OMER)

Nasdaq: OMER · Pharmaceutical Preparations · Seattle, WA · filing with the SEC since 2004
Full chart Alerts Compare
Grade4.6
◀ Past 6.2● Present 5.6▶ Future 2.7
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2020, as filed
Revenue$73.8M-34.0%
Net income-$138M-63.4%
Earnings per share$-2.41-40.9%
Operating cash flow-$100M-66.6%
Cash$10.5M+240.5%
Debt$236M+181.9%
Shareholders’ equity-$121M-10.8%
Shares, diluted57.2M+15.5%
Return on equityn/a
The recordfrom its filings
Filings in 202654
Newest filingOct 30 · 8-K
Annual reportMar 31, 2026
Quarterly reportAug 12, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$3.0M
Insider buys, 12 months$0.00
Patents granted98
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Net income $125MCash from operations -$68.7Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
16171819202122232425
As filed, in USD. Nothing here is a forecast.

News

Oct 30, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Oct 30, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 24, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 1, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Aug 28, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton OMER · research, not advice